Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. abt

ABT

AXVIRIUM BIOACTIVE TECNOLOGY_ The first medical device able to eliminate the fluids biological hazard

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ABT project word cloud

Explore the words cloud of the ABT project. It provides you a very rough idea of what is the project "ABT" about.

tons    million    18    reg    facilities    hepatitis    day    commercial    efficiency    200    natural    individuals    diseases    almost    hazardous    eur    tecnology    cagr    molecules    segments    reducing    investigation    worldwide    abt    direct    amongst    skilled    rnases    positive    billion    healthcare    health    caused    23    employees    decreasing    solution    2018    estimate    14    innovative    feasibility    reduce    economic    accounted    global    improper    100    annually    time    2022    completely    hire    identification    hiv    adantium    posing    anticipated    7000    cross    infection    ip    fluids    axivirium    competitors    accidents    virus    disposal    nearly    biomedical    market    nosocomial    device    incorrect    imply    strategy    bioactive    biological    customer    8    20    occupational    16    validate    medical    risks    sterilize    fluid    environment    barriers    ing    21    survey    care    impacts    axvirium    39    66    plus    industry    saving    valuation    proper    infectious    waste    world    organisation    cut    community    structures    validation    degradation   

Project "ABT" data sheet

The following table provides information about the project.

Coordinator		 ENPROJECT MEDICALI SRL 

Organization address
address: VIALE CARLO FAINA 30
city: MARSCIANO
postcode: 6055
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Project website https://www.enprojectmedicali.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ENPROJECT MEDICALI SRL IT (MARSCIANO) coordinator 50˙000.00

Map

 Project objective

The aim of the project is to validate the technical and economic feasibility of AXVIRIUM BIOACTIVE TECNOLOGY (ABT) an innovative biomedical device, based on the Adantium® Plus and Axivirium BIOACTIVE® molecules, enable to cut biological risks, improve efficiency and reduce cost of health care biomedical fluids disposal. Medical waste is posing a growing problem worldwide resulting in nearly 7000 tons every day of infectious /hazardous medical waste and 10 billion euro annually in disposal cost across the European health care industry. According to the World Health Organisation (WHO), incorrect and improper management of healthcare biological fluids can have direct impacts on the community, individuals working in health care facilities, and the natural environment. It estimated that at world level accidents caused by not proper biological risks management accounted for 66,000 cases of infection with the hepatitis B virus, 16,000 cases of infection with hepatitis C virus and 200 to 5,000 cases of HIV infection amongst the personnel of health-care facilities. Compared to competitors ABT is the unique solution able to reach 100% degradation of RNases almost in real time and completely sterilize biological fluids. This imply saving operational cost up to 20%, decreasing occupational diseases by 39% and reducing cross- nosocomial infection by 14%. In 2018, the valuation of the global fluid management market was EUR 10 billion and is anticipated to reach EUR 18 billion by 2022, at a positive CAGR of 4.8% in the next three years. The estimated market potential for ABT is about 21 million euro and we estimate to hire 23 high skilled employees. The feasibility study comprises an investigation of market structures, segments and barriers, a customer survey and product validation, the identification of key commercial partners and the development of an IP strategy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ABT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ABT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More